Creo Medical Group PLC (AIM: CREO)
London
· Delayed Price · Currency is GBP · Price in GBX16.49
-0.26 (-1.55%)
Nov 20, 2024, 4:29 PM GMT+1
Creo Medical Group Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 30.3 | 30.8 | 27.2 | 25.16 | 9.43 | 0.01 | Upgrade
|
| Revenue | 30.3 | 30.8 | 27.2 | 25.16 | 9.43 | 0.01 | Upgrade
|
| Revenue Growth (YoY) | 3.41% | 13.24% | 8.10% | 166.85% | 69884.41% | - | Upgrade
|
| Cost of Revenue | 15.3 | 15.5 | 14 | 13.58 | 5.39 | 0.01 | Upgrade
|
| Gross Profit | 15 | 15.3 | 13.2 | 11.59 | 4.04 | 0 | Upgrade
|
| Selling, General & Admin | 40.8 | 40.5 | 44 | 41.54 | 27.57 | 19.01 | Upgrade
|
| Other Operating Expenses | -0.4 | -0.4 | -0.1 | -0.05 | -0.05 | -0.13 | Upgrade
|
| Operating Expenses | 40.4 | 40.1 | 43.9 | 41.49 | 27.52 | 18.88 | Upgrade
|
| Operating Income | -25.4 | -24.8 | -30.7 | -29.91 | -23.48 | -18.88 | Upgrade
|
| Interest Expense | -0.6 | -0.4 | -0.2 | -0.21 | -0.07 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.6 | 0.7 | 0.1 | 0.03 | 0.18 | 0.31 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0.1 | -0.25 | -0.09 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | -25.4 | -24.5 | -30.9 | -30.34 | -23.46 | -18.62 | Upgrade
|
| Other Unusual Items | 0.3 | - | - | - | - | - | Upgrade
|
| Pretax Income | -25.1 | -24.5 | -30.9 | -30.34 | -23.46 | -18.62 | Upgrade
|
| Income Tax Expense | -2.7 | -2.8 | -4 | -5.74 | -3.15 | -2.7 | Upgrade
|
| Net Income | -22.4 | -21.7 | -26.9 | -24.6 | -20.32 | -15.91 | Upgrade
|
| Net Income to Common | -22.4 | -21.7 | -26.9 | -24.6 | -20.32 | -15.91 | Upgrade
|
| Shares Outstanding (Basic) | 361 | 313 | 181 | 164 | 156 | 121 | Upgrade
|
| Shares Outstanding (Diluted) | 361 | 313 | 181 | 164 | 156 | 121 | Upgrade
|
| Shares Change (YoY) | 61.03% | 72.61% | 10.28% | 5.54% | 28.39% | 34.24% | Upgrade
|
| EPS (Basic) | -0.06 | -0.07 | -0.15 | -0.15 | -0.13 | -0.13 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.07 | -0.15 | -0.15 | -0.13 | -0.13 | Upgrade
|
| Free Cash Flow | -21.4 | -22.8 | -28.1 | -31.99 | -16.77 | -12.34 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.07 | -0.15 | -0.19 | -0.11 | -0.10 | Upgrade
|
| Gross Margin | 49.50% | 49.68% | 48.53% | 46.04% | 42.79% | 36.75% | Upgrade
|
| Operating Margin | -83.83% | -80.52% | -112.87% | -118.86% | -249.06% | -140097.81% | Upgrade
|
| Profit Margin | -73.93% | -70.45% | -98.90% | -97.75% | -215.46% | -118096.56% | Upgrade
|
| Free Cash Flow Margin | -70.63% | -74.03% | -103.31% | -127.13% | -177.80% | -91563.05% | Upgrade
|
| EBITDA | -22.7 | -22.2 | -28.5 | -28.15 | -22.49 | -18.46 | Upgrade
|
| EBITDA Margin | -74.92% | -72.08% | -104.78% | -111.88% | -238.54% | - | Upgrade
|
| D&A For EBITDA | 2.7 | 2.6 | 2.2 | 1.76 | 0.99 | 0.41 | Upgrade
|
| EBIT | -25.4 | -24.8 | -30.7 | -29.91 | -23.48 | -18.88 | Upgrade
|
| EBIT Margin | -83.83% | -80.52% | -112.87% | -118.86% | -249.06% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.